Background To describe and report the efficacy and safety of MR-guided laser interstitial thermal therapy(MRgLITT)in the treatment of drug-resistant epilepsy.Methods A retrospective review of all MRgLITT procedures in...Background To describe and report the efficacy and safety of MR-guided laser interstitial thermal therapy(MRgLITT)in the treatment of drug-resistant epilepsy.Methods A retrospective review of all MRgLITT procedures in our hospital was performed.All procedures were performed using a surgical laser ablation system.Demographic and outcome data were compiled and analyzed.Results A total of 19 patients underwent MRgLITT procedures from June 2021 to November 2021.The average age at surgery was 18.1 years(3-61.4 years).The average length of hospitalization post-surgery was 4.95 days(4-7 days).Surgical substrates included 8 patients with hypothalamic hamartomas,5 with medial temporal lobe epilepsy,3 with deep focal cortical dysplasia,1 with tuberous sclerosis,1 with a cavernous malformation,and 1 with Lennox-Gastaut syndrome who underwent anterior corpus callosotomy.Complications occurred in three patients.After an average follow-up of 1 year,6 patients were seizure-free(Engel I,31.6%),1 had significant seizure control(Engel II,5.3%),7 had seizure control(Engel III,36.8%),and 5 had no improvement in their seizures(Engel IV,26.3%).Fisher’s exact tests did not reveal statistical significance for the association between Engel class outcome and epileptic disease.Conclusion This study confirmed that MRgLITT,as a method for treating drug-resistant epilepsy,is minimally invasive,safe,and efficient and that it can reduce the incidence of surgery-related complications.展开更多
文摘Background To describe and report the efficacy and safety of MR-guided laser interstitial thermal therapy(MRgLITT)in the treatment of drug-resistant epilepsy.Methods A retrospective review of all MRgLITT procedures in our hospital was performed.All procedures were performed using a surgical laser ablation system.Demographic and outcome data were compiled and analyzed.Results A total of 19 patients underwent MRgLITT procedures from June 2021 to November 2021.The average age at surgery was 18.1 years(3-61.4 years).The average length of hospitalization post-surgery was 4.95 days(4-7 days).Surgical substrates included 8 patients with hypothalamic hamartomas,5 with medial temporal lobe epilepsy,3 with deep focal cortical dysplasia,1 with tuberous sclerosis,1 with a cavernous malformation,and 1 with Lennox-Gastaut syndrome who underwent anterior corpus callosotomy.Complications occurred in three patients.After an average follow-up of 1 year,6 patients were seizure-free(Engel I,31.6%),1 had significant seizure control(Engel II,5.3%),7 had seizure control(Engel III,36.8%),and 5 had no improvement in their seizures(Engel IV,26.3%).Fisher’s exact tests did not reveal statistical significance for the association between Engel class outcome and epileptic disease.Conclusion This study confirmed that MRgLITT,as a method for treating drug-resistant epilepsy,is minimally invasive,safe,and efficient and that it can reduce the incidence of surgery-related complications.
